There are currently 604 clinical trials in Richmond, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Virginia Commonwealth University, Virginia Commonwealth University/Massey Cancer Center, VCU Massey Comprehensive Cancer Center and Virginia Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Richmond, Virginia
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Richmond VA Medical Center, Richmond, Virginia
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT02843945
Recruiting
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Conditions: Pancreatic Cancer
Register for Updates
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
NCT06011551
Recruiting
A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
06/16/2025
Locations: Virginia iSpine Physicians, Richmond, Virginia
Conditions: Degenerative Disc Disease (DDD)
Register for Updates
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
NCT05446272
Recruiting
DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.
Gender:
ALL
Ages:
Between 0 days and 9 weeks
Trial Updated:
06/13/2025
Locations: Children's Hospital of Richmond, Richmond, Virginia
Conditions: Extubation Failure, Bronchopulmonary Dysplasia, Death
Register for Updates
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease
NCT06613698
Recruiting
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2025
Locations: GSK Investigational Site, Richmond, Virginia
Conditions: Liver Diseases, Alcoholic
Register for Updates
Study of LYL314 in Aggressive Large B-Cell Lymphoma
NCT05826535
Recruiting
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Virginia Commonwealth University-Massey Cancer Center, Richmond, Virginia
Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Conditions: Breast Cancer
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
06/10/2025
Locations: CJW Medical Center - Johnston-Willis Campus, Richmond, Virginia
Conditions: Breast Cancer
Register for Updates
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06235697
Recruiting
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Bon Secours Cancer Institute at Reynolds Crossing, Richmond, Virginia +1 locations
Conditions: Prostate Cancer
Register for Updates
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
NCT06987513
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2025
Locations: Altimmune Clinical Study Site, Richmond, Virginia
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Improving Exercise Capacity With a Tailored Physical Activity Intervention
NCT05595577
Recruiting
The purpose of this research is to test whether participating in either a physical activity intervention or a series of educational classes will help to preserve exercise capability, heart function, brain-based activities (like memory), and quality of life. Participants will be randomized to 1 of 2 pathways: * First pathway consists of organized health workshops. These workshops are intended to provide information on topics such as proper nutrition, management of stress, sleep practices, and e... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/09/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Non Hodgkin Lymphoma, Heart; Functional Disturbance, Hodgkin Lymphoma, Quality of Life, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Register for Updates